企業プロフィール
Teva Pharmaceutical Industries 株価・ニュース・カタリスト
- ティッカー:
- TEVA
- 取引所:
- NYSE
- セクター:
- Biopharma
- 所在地:
- Israel and listed in the U
株価パフォーマンス
36.46 USD (-0.84%)
終値
最終更新: 2026年8月17日
38.5B USD
時価総額
株価変動の要因
As of Aug 17, 2026, TEVA closed down 0.84% at $36.46. No new same-company headline was identified in the current news window.
企業概要
Global Generics and Innovative Medicines Company
Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio. Its current strategy, Pivot to Growth, is shifting the company toward higher-value innovative brands, biosimilars, and late-stage pipeline assets while modernizing operations.
Innovative Brand Growth
Teva's key innovative brands are AUSTEDO, AJOVY, and UZEDY. Together they generated more than $1 billion in second-quarter 2026 revenue and grew 43% year over year in local currency. This portfolio is transforming Teva's revenue mix and supports the company's raised 2026 outlook for all three brands.
Generics and Biosimilars Powerhouse
Generics revenue declined in the quarter, largely due to lower U.S. lenalidomide revenue as competition increased. At the same time, Teva is building biosimilars as a growth area, including the European launch of AHZANTIVE and a collaboration with Polpharma Biologics for a proposed Ocrevus biosimilar.
Late-Stage Neuroscience and Immunology Pipeline
Teva is expanding its innovative pipeline through assets such as ecopipam for Tourette syndrome, olanzapine LAI for schizophrenia, TEV-'408 for vitiligo, and duvakitug with Sanofi for inflammatory bowel disease and additional immune-mediated indications. This gives the company a more diversified growth profile beyond mature generics.
今後のカタリスト
- Potential U.S. launch of olanzapine LAI in the fourth quarter of 2026, subject to approval.
- FDA review of ecopipam after NDA submission in June 2026.
- Phase 2 initiation for TEV-'408 in vitiligo expected in the fourth quarter of 2026.
- Additional duvakitug studies in hidradenitis suppurativa and fibrostenotic Crohn's disease.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。